Table 2.

Odds ratios for early response to treatment measured by fold change in C6M from baseline to week 4

Response (week 16)	ΔC6Mw4
	TCZ4 + MTX					TCZ8 + MTX					Placebo + MTX
	OR	CI lower	CI upper	p	p.adj	OR	CI lower	CI upper	p	p.adj	OR	CI lower	CI upper	p	p.adj
Early non-responder
Unadjusted	1.27	0.83	1.99	0.279	0.348	1.50	0.99	2.29	0.058	0.115	0.77	0.51	1.13	0.188	0.269
Adjusted	1.28	0.83	2.03	0.267	0.334	1.52	0.99	2.36	0.059	0.117	0.76	0.50	1.13	0.182	0.261
DAS remission (< 2.6)
Unadjusted	0.74	0.40	1.38	0.345	0.383	0.44	0.26	0.70	0.001	0.011	-	-	-	-	-
Adjusted	0.77	0.43	1.38	0.390	0.433	0.41	0.24	0.66	< 0.001	0.005	-	-	-	-	-
DAS reduction (< 3.2)
Unadjusted	0.67	0.41	1.05	0.085	0.141	0.59	0.39	0.86	0.008	0.038	-	-	-	-	-
Adjusted	0.67	0.42	1.06	0.091	0.152	0.52	0.34	0.77	0.002	0.008	-	-	-	-	-
ACR50
Unadjusted	0.62	0.40	0.95	0.031	0.076	0.64	0.43	0.93	0.021	0.071	0.86	0.46	1.63	0.635	0.635
Adjusted	0.62	0.40	0.96	0.035	0.088	0.62	0.42	0.89	0.012	0.041	0.86	0.45	1.63	0.634	0.634

Adjusted for sex, age, and BMI

Odds ratio of response per 2-fold increase in ratio from baseline in C6M, a p-value < 0.05 was considered statistically significant